Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis

Journal of Clinical Pharmacology

Volumn 44, Issue 11, 2004, Pages 1235-1243

  Zhou, Honghui ^a   Mayer, Philip R ^a   Wajdula, Joseph ^a   Fatenejad, Saeed ^a  

^a PFIZER INC   (United States)

Author keywords

Drug interaction; Etanercept; Methotrexate; NONMEM

Indexed keywords

ETANERCEPT; METHOTREXATE; PLACEBO;

ADULT; AGED; ARTHRITIS; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BAYES THEOREM; BIOLOGICAL AVAILABILITY; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; METABOLIC CLEARANCE RATE; METHOTREXATE; MIDDLE AGED; MODELS, BIOLOGICAL; RECEPTORS, TUMOR NECROSIS FACTOR; REPRODUCIBILITY OF RESULTS;

EID: 6344284247     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004268049     Document Type: Article

References (34)

1. Silman AJ, Hochberg MC, eds. Epidemiology of the Rheumatic Diseases. New York: Oxford University Press; 1993.
2. Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum. 1999;42:1854-1860.
3. Eberhardt KB, Fex E. Functional impairment and disability in early rheumatoid arthritis-development over 5 years. J Rheumatol. 1995;22:1037-1042.
4. Pincus T, Sokka T, Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concept [comment]. Arthritis Rheum. 2001;44:1234-1236.
5. Culy CR, Keating GM. Etanercept-an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs. 2002;62(17):2495-2539.
6. Wooley PH, Butcher J, Widmer MB, Gillis S. The influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol. 1993;151:6602-6607.
7. Lebsack ME, Hanna RK, Lange MA, Korth-Bradley J. Absolute bioavailability of TNF receptor fusion protein following subcutaneous injection in healthy volunteers [abstract 233]. Pharmacotherapy. 1997;17(5):1118.
8. European Agency for Evaluation of Medicinal Products. Scientific discussion: Enbrel. Accessed September 2003 from www.emea.eu.int
9. Immunex. Enbrel® (etanercept) prescribing information. Accessed September 2003 from www.immunex.com
10. Zhou H, Patat A, Parks V, Buckwalter M, Metzger D, Korth-Bradley J. Absence of a pharmacokinetic interaction between etanercept and warfarin. J Clin Pharmacol. 2004;44:543-550.
11. Zhou H, Parks V, Patat A, Le Coz F, Simcoe D, Korth-Bradley J. Absence of a clinically relevant interaction between etanercept and digoxin. J Clin Pharmacol. 2004;44:1244-1256.
12. Haagsma CJ, Russel FGM, Vree TB, Van Riel PLCM, Van De Putte LBA. Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. Br J Clin Pharmacol. 1996;42:195-200.
13. Chladek J, Martinkova J, Simkova M, Vaneckova J, Koudelkova V, Nozickova M. Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol. 1998;53:437-444.
14. Bannwarth B, Labat L, Moride Y, Schaeverbeke T. Methotrexate in rheumatoid arthritis: an update. Drugs. 1994;47:25-50.
15. Johns DG, Iannotti AT, Sartorelli AC, Booth BA, Bertino JR. The identity of rabbit-liver methotrexate oxidase. Biochem Biophys Acta. 1965;105:380-382.
16. Jordan CG, Rashidi MR, Laljee H, Clarke SE, Brown JE, Beedham C. Aldehyde oxidase-catalysed oxidation of methotrexate in the liver of guinea-pig, rabbit and man. J Pharm Pharmacol. 1999;51:411-418.
17. Baumhakel M, Kasel D, Rao-Schymanski RA, et al. Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharm Ther. 2001;39:517-528.
18. Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2001;40(10):723-751.
19. FDA approved label for HUMIRA (adalimumab); 2003.
20. Awni WM, Cascella P, Oleka NA, et al. Steady-state pharmacokinetics (PK) of adlimumab (HUMIRA®, Abbott) following 40 mg subcutaneous (sc) injection every other week (eow) in rheumatoid arthritis (RA) patients with and without methotrexate (MTX) background therapy. Arthritis Rheum. 2003;48(9):S140.
21. Velagapudi RB, Noertersheuser PA, Awni WM, et al. Effect of methotrexate (MTX) coadministration on the pharmacokinetics (PK) of adalimumab (HUMIRA, Abbott) following a single intravenous (iv) injection. Arthritis Rheum. 2003;48(9):S141.
22. Klareskog L, van der Heijde D, de Jager P, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis. Lancet. 2004;363:675-681.
23. Zhou H. Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol. 2003;43:211-227.
24. Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther. 2003;73:348-365.
25. Zhou H, Buckwalter M, Boni J, et al. Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2004;42(5):267-276.
26. Ronfeld R, Benet LZ. Interpretation of plasma concentration-time curves after oral dosing. J Pharm Sci. 1977;66(2):178-180.
27. Yukawa E. Population-based investigations of drug relative clearance using nonlinear mixed-effect modeling from information generated during the routine clinical care of patients. J Clin Pharm Ther. 1999;24:103-113.
28. Yukawa E, Aoyama T. Detecting of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data. J Clin Pharmacol. 1996;36(8):752-759.
29. Yukawa E, Hokazono T, Satou M, Ohdo S, Higuchi S, Aoyama T. Pharmacokinetic interactions among phenobarbital, carbamazepine, and valproic acid in pediatric Japanese patients: clinical considerations on steady-state serum concentration-dose ratios. Am J Ther. 2000;7(5):303-308.
30. Yukawa E, To H, Ohdo S, Higuchi S, Aoyama T. Detection of a drug-drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling. Eur J Clin Pharmacol. 1998;54(1):69-74.
31. Yukawa E, To H, Ohdo S, Higuchi S, Aoyama T. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. J Clin Pharmacol. 1997;37(12):1160-1167.
32. Bauer LA, Horn JR, Pettit H. Mixed-effect modeling for detection and evaluation of drug interactions: digoxin-quinidine and digoxin-verapamil combinations. Ther Drug Monit. 1996;18(1):46-52.
33. Grasela TH Jr, Antal EJ, Ereshefsky L, Wells BG, Evans RL, Smith RB. An evaluation of population pharmacokinetics in therapeutic trials: Part II. Detection of a drug-drug interaction. Clin Pharmacol Ther. 1987;42(4):433-441.
34. Food and Drug Administration. Guidance for Industry: Population Pharmacokinetics. Rockville, MD: Department of Health and Human Services; 1999.